Ipsen media releases

Key highlights

Ipsen delivers robust sales growth in the first quarter of 2023 and confirms its full-year guidance

– 27 April 2023 – 1 mins read

27 April 2023 – 1 mins read

Ipsen delivers robust sales growth in the first quarter of 2023 and confirms its full-year guidance

Paris (France), 27 April 2023

Filter

Topics

Period

Filter by

Reset

Showing: 1 – 05 of 30 Press Releases

Show

Sort

Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio

– 02 March 2023

02 March 2023

Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio

PARIS, FRANCE, 3 March 2023 – Ipsen (Euronext: IPN: ADR: IPSEY) today announced it has completed the acquisition of Albireo Pharma, Inc., a leading innovator in bile-acid modulators to treat rare liver conditions. The acquisition enriches Ipsen’s

Ipsen extends expiration date of tender offer for Albireo Pharma, Inc. to 1 March 2023

– 22 February 2023

22 February 2023

Ipsen extends expiration date of tender offer for Albireo Pharma, Inc. to 1 March 2023

PARIS, FRANCE, 22 February 2023 – Ipsen S.A. (Euronext: IPN; ADR: IPSEY) today announced that Anemone Acquisition Corp. (Purchaser), its wholly owned indirect subsidiary, has extended the expiration time for the previously announced tender offer to

Ipsen, Université de Montréal and IRICoR broaden existing oncology partnership, with an exclusive license agreement and two new discovery-stage programs

– 15 February 2023

15 February 2023

Ipsen, Université de Montréal and IRICoR broaden existing oncology partnership, with an exclusive license agreement and two new discovery-stage programs

PARIS, FRANCE, MONTREAL, CANADA 15 February 2023 – Ipsen (Euronext: IPN; ADR: IPSEY), Université de Montréal and IRICoR announce that Ipsen has exercised its option to acquire exclusive rights to a pre-clinical stage program with potential oncolog

Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma

– 13 February 2023

13 February 2023

Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma

CORRECTED and REPLACING: Minor updates were made on 24 April 2023 to correct an error in the original data analysis impacting the blinded independent central reviewer (BICR)-assessed data points (PFS, ORR, and DoR). The safety and efficacy profile, includi

Ipsen presents strong full-year 2022 results and guidance for 2023

– 09 February 2023

09 February 2023

Ipsen presents strong full-year 2022 results and guidance for 2023

Paris (France), 9 February 2023

1 2 3 4 5 6

Your dedicated contacts

Amy Wolf

Vice President, Corporate Brand Strategy and Communications

Ioana Piscociu

Senior Manager, Media Relations

Press Releases